article thumbnail

The Ethical Challenges for Pharmaceutical Marketers in Using AI to Write Marketing Copy or Creative

Pharma Marketing Network

While AI can be a powerful tool for creating effective marketing campaigns, it also poses significant ethical challenges. One of the main ethical concerns with using AI in pharmaceutical marketing is the potential for the technology to perpetuate biases and discrimination. “The ethics of artificial intelligence.”

Ethics 52
article thumbnail

Data integrity considerations in Pharma and Life Sciences

European Pharmaceutical Review

Life science companies are increasingly using advanced technologies like artificial intelligence (AI), machine learning (ML) and blockchain to improve data quality and integrity by detecting anomalies in data and establishing tamper-proof audit trails for all data-related activities Data governance.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Aggressive Selling: The High-Stakes Game of Push and Profit

Contrarian Sales Techniques

Ethical Considerations: The Fine Line in Sales The Question of Morality in Sales Techniques The ethics of aggressive selling are often debated. Regulatory Scrutiny and Consumer Protection Governments and consumer protection agencies have started scrutinizing aggressive selling techniques.

Ethics 40
article thumbnail

How do Healthcare AI Developers (and Buyers) Stay Ahead of the Regulatory Curve?

Nixon Gwilt Law

Its three separate Rules (Security, Privacy, and Breach) impose a variety of security controls, documentation, governance, and notice requirements on custodians of protected health information (PHI). The HTI-1 Final Rule is an AI disclosure and governance rule published by the US Department of Health and Human Services (HHS).

article thumbnail

Why Is FDA Issuing Fewer Marketing Violation Letters?

Pharma Marketing Network

While maintaining a vigilant approach to marketing compliance is crucial, the FDA may be strategically choosing to address more immediate public health concerns, leading to fewer marketing violation letters being issued. The post Why Is FDA Issuing Fewer Marketing Violation Letters? appeared first on Pharma Marketing Network.

article thumbnail

Revolutionizing Rare Disease Research: Unleashing the Power of Patient Advocacy and Artificial Intelligence

PM360

Their impact extends beyond increasing participant numbers, encompassing broader contributions to research design, ethics, and addressing logistical barriers 2. AI can contribute to these strategies by providing data-driven insights, supporting informed decision-making, and enhancing overall collaboration.

article thumbnail

Strengthening and transforming the pharmaceutical supply chain

European Pharmaceutical Review

While supply chain challenges became evident during the pandemic, several regions worldwide still face issues leading to product shortages. There is an increasing focus on sustainability and Environmental, Social, and Governance (ESG) factors in supply chain management.